Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
75 hedge funds and large institutions have $585M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2017 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 13 reducing their positions, and 13 closing their positions.
307% more call options, than puts
Call options by funds: $1.05M | Put options by funds: $258K
138% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 13
74% more capital invested
Capital invested by funds: $335M → $585M (+$250M)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
9% more funds holding
Funds holding: 69 → 75 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$60M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$14.2M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$13M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$6.18M |
| 5 |
PA
Perceptive Advisors
New York
|
+$5.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$13.7M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$7.72M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$4.62M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.74M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.71M |
BHVN Hedge Fund Activity: Q3 2017 in Review
75 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q3 2017, worth a combined $585M — up 74% from $335M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new BHVN positions and 13 closed out — a net gain of 6 holders — while 31 added to existing stakes and 13 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $60M. The largest seller was RA Capital Management, cutting an estimated $13.7M.
- 75 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q3 2017, up from 69 in Q2 2017.
- Funds reported $585M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q3 2017, up 74% quarter-over-quarter.
- 19 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q3 2017 and 13 closed out, a net change of +6 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q3 2017 was Vivo Capital, an estimated $60M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q3 2017 was RA Capital Management, an estimated $13.7M sold.
Based on aggregated 13F filings for Q3 2017.